Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Long-Term Deferred Tax (2018 - 2021)

Cytosorbents (CTSO) has disclosed Long-Term Deferred Tax for 4 consecutive years, with $4.1 million as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Long-Term Deferred Tax fell 83.87% year-over-year to $4.1 million, compared with a TTM value of $4.1 million through Dec 2021, down 83.87%, and an annual FY2021 reading of $4.1 million, down 83.87% over the prior year.
  • Long-Term Deferred Tax was $4.1 million for Q4 2021 at Cytosorbents, down from $25.2 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $25.2 million in Q4 2020 and bottomed at $21856.0 in Q4 2018.
  • Average Long-Term Deferred Tax over 4 years is $7.4 million, with a median of $2.2 million recorded in 2019.
  • The sharpest move saw Long-Term Deferred Tax skyrocketed 6304.2% in 2020, then crashed 83.87% in 2021.
  • Year by year, Long-Term Deferred Tax stood at $21856.0 in 2018, then surged by 1702.24% to $393897.0 in 2019, then surged by 6304.2% to $25.2 million in 2020, then plummeted by 83.87% to $4.1 million in 2021.
  • Business Quant data shows Long-Term Deferred Tax for CTSO at $4.1 million in Q4 2021, $25.2 million in Q4 2020, and $393897.0 in Q4 2019.